CN107698591A - (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法 - Google Patents
(6s)-5-甲基四氢叶酸锌盐晶型及其制备方法 Download PDFInfo
- Publication number
- CN107698591A CN107698591A CN201510631169.1A CN201510631169A CN107698591A CN 107698591 A CN107698591 A CN 107698591A CN 201510631169 A CN201510631169 A CN 201510631169A CN 107698591 A CN107698591 A CN 107698591A
- Authority
- CN
- China
- Prior art keywords
- zinc
- acid
- preparation
- crystal formation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 50
- 239000013078 crystal Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- OVEZCAYFYJQDQV-ZEXVLMPOSA-L [Zn+2].CN1C=2C(NC(=NC2NC[C@@H]1CNC1=CC=C(C(N[C@@H](CCC(=O)[O-])C(=O)O)=O)C=C1)N)=O.CN1C=2C(NC(=NC2NC[C@@H]1CNC1=CC=C(C(N[C@@H](CCC(=O)[O-])C(=O)O)=O)C=C1)N)=O Chemical compound [Zn+2].CN1C=2C(NC(=NC2NC[C@@H]1CNC1=CC=C(C(N[C@@H](CCC(=O)[O-])C(=O)O)=O)C=C1)N)=O.CN1C=2C(NC(=NC2NC[C@@H]1CNC1=CC=C(C(N[C@@H](CCC(=O)[O-])C(=O)O)=O)C=C1)N)=O OVEZCAYFYJQDQV-ZEXVLMPOSA-L 0.000 title claims description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000000243 solution Substances 0.000 claims abstract description 29
- 239000011578 levomefolic acid Substances 0.000 claims abstract description 24
- 239000007853 buffer solution Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 19
- 239000011701 zinc Substances 0.000 claims abstract description 19
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 19
- 239000002253 acid Substances 0.000 claims abstract description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000007935 neutral effect Effects 0.000 claims abstract description 15
- 235000007635 levomefolic acid Nutrition 0.000 claims abstract description 14
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 5
- 239000003513 alkali Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 26
- 239000000872 buffer Substances 0.000 claims description 18
- 235000019152 folic acid Nutrition 0.000 claims description 15
- 239000011724 folic acid Substances 0.000 claims description 15
- 235000002639 sodium chloride Nutrition 0.000 claims description 14
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 12
- 229960000304 folic acid Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000007974 sodium acetate buffer Substances 0.000 claims description 9
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 9
- 238000001228 spectrum Methods 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 229960002319 barbital Drugs 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- -1 neutral Substances 0.000 claims description 6
- 239000007981 phosphate-citrate buffer Substances 0.000 claims description 6
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013904 zinc acetate Nutrition 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- 239000012670 alkaline solution Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 4
- HXMWJLVXIHYART-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide;hydrochloride Chemical compound [OH-].[Na+].Cl.OC(=O)CC(O)(C(O)=O)CC(O)=O HXMWJLVXIHYART-UHFFFAOYSA-M 0.000 claims description 4
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 claims description 4
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 4
- SWSHKRHJENMKJJ-UHFFFAOYSA-L O.[Na+].P(=O)(O)(O)[O-].[K+].P(=O)(O)(O)[O-] Chemical compound O.[Na+].P(=O)(O)(O)[O-].[K+].P(=O)(O)(O)[O-] SWSHKRHJENMKJJ-UHFFFAOYSA-L 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 229910052786 argon Inorganic materials 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 150000004885 piperazines Chemical class 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000004323 potassium nitrate Substances 0.000 claims description 2
- 235000010333 potassium nitrate Nutrition 0.000 claims description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 2
- 235000011151 potassium sulphates Nutrition 0.000 claims description 2
- 150000003222 pyridines Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 229940007718 zinc hydroxide Drugs 0.000 claims description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229960001763 zinc sulfate Drugs 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims 3
- 238000011010 flushing procedure Methods 0.000 claims 3
- ZYXXVFFNLGOKRC-UHFFFAOYSA-N O.[Na].[K] Chemical compound O.[Na].[K] ZYXXVFFNLGOKRC-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- 238000002479 acid--base titration Methods 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000000337 buffer salt Substances 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000007086 side reaction Methods 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 description 34
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010048259 Zinc deficiency Diseases 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 8
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 6
- JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical class [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 4
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical class C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000036301 sexual development Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KXOSVTXKUOZYQR-MMFRDWCLSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;azane Chemical class N.C1NC=2NC(N)=NC(=O)C=2NC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 KXOSVTXKUOZYQR-MMFRDWCLSA-N 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 206010002064 Anaemia macrocytic Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940047766 co-trimoxazole Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 201000006437 macrocytic anemia Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 201000004625 Acrodermatitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- JGPSMWXKRPZZRG-UHFFFAOYSA-N zinc;dinitrate;hexahydrate Chemical class O.O.O.O.O.O.[Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O JGPSMWXKRPZZRG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
# | 2-Theta | d(A) | BG | Height | I% | Area | I% | FWHM |
1 | 8.560 | 10.3213 | 52 | 172 | 20.3 | 1371 | 19.4 | 0.271 |
2 | 10.281 | 8.5969 | 40 | 484 | 57.1 | 3795 | 53.7 | 0.267 |
3 | 12.158 | 7.2736 | 34 | 543 | 64.0 | 5356 | 75.8 | 0.335 |
4 | 13.203 | 6.7003 | 114 | 606 | 71.5 | 3471 | 49.1 | 0.195 |
5 | 13.804 | 6.4096 | 52 | 41 | 4.8 | 93 | 1.3 | 0.077 |
6 | 14.601 | 6.0618 | 44 | 291 | 34.3 | 2151 | 30.4 | 0.251 |
7 | 16.764 | 5.2840 | 61 | 273 | 32.2 | 2106 | 29.8 | 0.262 |
8 | 17.228 | 5.1429 | 68 | 51 | 6.0 | 326 | 4.6 | 0.217 |
9 | 17.962 | 4.9343 | 59 | 559 | 65.9 | 4179 | 59.1 | 0.254 |
10 | 18.401 | 4.8176 | 49 | 65 | 7.7 | 459 | 6.5 | 0.240 |
11 | 19.756 | 4.4901 | 40 | 664 | 78.3 | 7066 | 100.0 | 0.362 |
12 | 20.683 | 4.2910 | 90 | 563 | 66.4 | 3386 | 47.9 | 0.204 |
13 | 21.721 | 4.0881 | 99 | 848 | 100.0 | 6625 | 93.8 | 0.266 |
14 | 22.717 | 3.9112 | 59 | 310 | 36.6 | 3276 | 46.4 | 0.359 |
15 | 23.916 | 3.7177 | 74 | 115 | 13.6 | 672 | 9.5 | 0.199 |
16 | 24.719 | 3.5987 | 76 | 337 | 39.7 | 3314 | 46.9 | 0.334 |
17 | 25.325 | 3.5139 | 83 | 52 | 6.1 | 378 | 5.3 | 0.247 |
18 | 26.442 | 3.3680 | 95 | 224 | 26.4 | 1368 | 19.4 | 0.208 |
19 | 27.205 | 3.2752 | 78 | 149 | 17.6 | 1732 | 24.5 | 0.395 |
20 | 27.841 | 3.2018 | 51 | 322 | 38.0 | 2682 | 38.0 | 0.283 |
21 | 28.919 | 3.0849 | 60 | 47 | 5.5 | 548 | 7.8 | 0.396 |
22 | 29.362 | 3.0393 | 68 | 67 | 7.9 | 791 | 11.2 | 0.401 |
23 | 30.200 | 2.9569 | 67 | 128 | 15.1 | 1259 | 17.8 | 0.334 |
24 | 31.318 | 2.8539 | 56 | 85 | 10.0 | 577 | 8.2 | 0.231 |
25 | 31.997 | 2.7948 | 64 | 35 | 4.1 | 155 | 2.2 | 0.151 |
26 | 32.596 | 2.7448 | 57 | 73 | 8.6 | 1282 | 18.1 | 0.597 |
27 | 33.001 | 2.7120 | 61 | 154 | 18.2 | 1483 | 21.0 | 0.327 |
28 | 34.077 | 2.6288 | 58 | 214 | 25.2 | 1580 | 22.4 | 0.251 |
29 | 34.678 | 2.5846 | 64 | 51 | 6.0 | 199 | 2.8 | 0.133 |
30 | 35.527 | 2.5248 | 68 | 36 | 4.2 | 117 | 1.7 | 0.111 |
31 | 36.399 | 2.4663 | 66 | 33 | 3.9 | 466 | 6.6 | 0.480 |
32 | 37.043 | 2.4249 | 67 | 44 | 5.2 | 365 | 5.2 | 0.282 |
33 | 37.522 | 2.3950 | 65 | 72 | 8.5 | 1150 | 16.3 | 0.543 |
34 | 37.874 | 2.3736 | 76 | 41 | 4.8 | 479 | 6.8 | 0.397 |
35 | 39.756 | 2.2654 | 87 | 73 | 8.6 | 465 | 6.6 | 0.217 |
36 | 40.401 | 2.2307 | 69 | 99 | 11.7 | 1467 | 20.8 | 0.504 |
37 | 41.881 | 2.1552 | 61 | 66 | 7.8 | 567 | 8.0 | 0.292 |
38 | 42.719 | 2.1149 | 65 | 85 | 10.0 | 1453 | 20.6 | 0.581 |
39 | 45.402 | 1.9959 | 57 | 31 | 3.7 | 463 | 6.6 | 0.508 |
40 | 45.721 | 1.9827 | 54 | 34 | 4.0 | 647 | 9.2 | 0.647 |
41 | 47.521 | 1.9118 | 42 | 31 | 3.7 | 332 | 4.7 | 0.364 |
42 | 50.997 | 1.7893 | 43 | 49 | 5.8 | 412 | 5.8 | 0.286 |
43 | 52.995 | 1.7265 | 44 | 27 | 3.2 | 351 | 5.0 | 0.442 |
44 | 53.953 | 1.6981 | 42 | 39 | 4.6 | 374 | 5.3 | 0.326 |
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510631169.1A CN107698591A (zh) | 2015-09-25 | 2015-09-25 | (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510631169.1A CN107698591A (zh) | 2015-09-25 | 2015-09-25 | (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107698591A true CN107698591A (zh) | 2018-02-16 |
Family
ID=61168209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510631169.1A Pending CN107698591A (zh) | 2015-09-25 | 2015-09-25 | (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107698591A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1277197A (zh) * | 1999-04-15 | 2000-12-20 | 阿泼洛发公司 | 5-甲基四氢叶酸的稳定晶体盐 |
CN102584826A (zh) * | 2012-01-20 | 2012-07-18 | 连云港金康医药科技有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
CN102702200A (zh) * | 2012-04-25 | 2012-10-03 | 连云港金康和信药业有限公司 | (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法 |
CN102775408A (zh) * | 2012-01-20 | 2012-11-14 | 连云港金康医药科技有限公司 | 稳定的无定型5-甲基四氢叶酸盐及其制备方法 |
CN104530051A (zh) * | 2012-01-20 | 2015-04-22 | 连云港金康医药科技有限公司 | 稳定的(6r,s)-5-甲基四氢叶酸晶型及其制备方法 |
CN104557937A (zh) * | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
-
2015
- 2015-09-25 CN CN201510631169.1A patent/CN107698591A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1277197A (zh) * | 1999-04-15 | 2000-12-20 | 阿泼洛发公司 | 5-甲基四氢叶酸的稳定晶体盐 |
CN102584826A (zh) * | 2012-01-20 | 2012-07-18 | 连云港金康医药科技有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
CN102775408A (zh) * | 2012-01-20 | 2012-11-14 | 连云港金康医药科技有限公司 | 稳定的无定型5-甲基四氢叶酸盐及其制备方法 |
CN104530051A (zh) * | 2012-01-20 | 2015-04-22 | 连云港金康医药科技有限公司 | 稳定的(6r,s)-5-甲基四氢叶酸晶型及其制备方法 |
CN104557937A (zh) * | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
CN102702200A (zh) * | 2012-04-25 | 2012-10-03 | 连云港金康和信药业有限公司 | (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102702200B (zh) | (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法 | |
CN102584826B (zh) | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 | |
CN104557937B (zh) | (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法 | |
EP2805952B1 (en) | Crystal form of (6s)-5-methyltetrahydrofolate salt and method for preparing same | |
CN102775408B (zh) | 稳定的5-甲基四氢叶酸晶型及其制备方法 | |
CN101209975A (zh) | 左旋肉碱富马酸钙及其制备方法与用途 | |
CN107698591A (zh) | (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法 | |
CN105237539A (zh) | A晶型(6s)-5-甲基四氢叶酸锌盐及其制备方法 | |
CN108373421B (zh) | 一种l-天门冬氨酸螯合钙的制备方法 | |
CN107892692A (zh) | (6s)‑5‑甲基四氢叶酸锌盐的制备方法及其应用 | |
CN102775407B (zh) | 稳定的无定型5-甲基四氢叶酸盐及其制备方法 | |
CN100455575C (zh) | 异硒唑酮类化合物和其配合物及其应用 | |
EP3653633A1 (en) | Methionine-metal chelate and production method thereof | |
EP3653632A1 (en) | Methionine-metal chelate and production method thereof | |
CN104530051A (zh) | 稳定的(6r,s)-5-甲基四氢叶酸晶型及其制备方法 | |
US20230416253A1 (en) | Folate salts | |
CN103172547A (zh) | 磺酰胺衍生物的制备及其应用 | |
CN103159649A (zh) | 磺酰胺类化合物的制备及其应用 | |
CN117143152A (zh) | 一种高纯度环保型l-抗坏血酸-2-磷酸酯镁盐合成工艺 | |
CN115160192A (zh) | 一种2-胍基乙烷-1-磺酸二十八烷基酯、其制备方法及其用途 | |
CN103374036A (zh) | 一种维生素c衍生物的合成工艺 | |
CN1098861C (zh) | 氨基葡萄糖金属配合物的制备方法 | |
CN105418501B (zh) | 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 | |
CN114773295A (zh) | 一种合成泛酸内酯的方法 | |
CN104592303A (zh) | 二(μ-)羟·四蛋氨酸合二铬(Ⅲ)及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Room 319, room No. 18, No. 1305, huhujing Road, Shanghai, Shanghai Applicant after: SHANGHAI HUALI BIOMEDICAL Co.,Ltd. Address before: Room 319, room No. 18, No. 1305, huhujing Road, Shanghai, Shanghai Applicant before: SHANGHAI ECUST BIOMEDICINE CO.,LTD. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180725 Address after: Room 202, room 109, Xuhui District chemical one village, Shanghai City, Shanghai Applicant after: Wu Fanhong Address before: Room 319, room No. 18, No. 1305, huhujing Road, Shanghai, Shanghai Applicant before: SHANGHAI HUALI BIOMEDICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180806 Address after: 321102 Lanxi Economic Development Zone, Jinhua, Zhejiang (room 2562, 500 Zhenxing Road, Lanjiang Street) Applicant after: Zhejiang Jia Tai Technology Co.,Ltd. Address before: Room 202, room 109, Xuhui District chemical one village, Shanghai City, Shanghai Applicant before: Wu Fanhong |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |
|
RJ01 | Rejection of invention patent application after publication |